CA2561738A1 - 1,3,4-oxadiazol-2-ones as ppar delta modulators_and their use thereof - Google Patents

1,3,4-oxadiazol-2-ones as ppar delta modulators_and their use thereof Download PDF

Info

Publication number
CA2561738A1
CA2561738A1 CA002561738A CA2561738A CA2561738A1 CA 2561738 A1 CA2561738 A1 CA 2561738A1 CA 002561738 A CA002561738 A CA 002561738A CA 2561738 A CA2561738 A CA 2561738A CA 2561738 A1 CA2561738 A1 CA 2561738A1
Authority
CA
Canada
Prior art keywords
phenyl
aryl
compound according
compound
6alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002561738A
Other languages
English (en)
French (fr)
Inventor
Daniel G. Mcgarry
Karen Chandross
Jean Merrill
Jochen Goerlitzer
Stefanie Keil
Wolfgang Wendler
Patrick Bernardelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2561738A1 publication Critical patent/CA2561738A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)
CA002561738A 2004-04-01 2005-03-30 1,3,4-oxadiazol-2-ones as ppar delta modulators_and their use thereof Abandoned CA2561738A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55841904P 2004-04-01 2004-04-01
US60/558,419 2004-04-01
PCT/US2005/010854 WO2005097762A2 (en) 2004-04-01 2005-03-30 1,3,4-oxadiazol-2-ones as ppar delta modulators

Publications (1)

Publication Number Publication Date
CA2561738A1 true CA2561738A1 (en) 2005-10-20

Family

ID=34972933

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002561738A Abandoned CA2561738A1 (en) 2004-04-01 2005-03-30 1,3,4-oxadiazol-2-ones as ppar delta modulators_and their use thereof

Country Status (17)

Country Link
US (1) US7576109B2 (https=)
EP (1) EP1735303B1 (https=)
JP (1) JP4813460B2 (https=)
KR (1) KR20060135854A (https=)
CN (1) CN100516065C (https=)
AT (1) ATE507226T1 (https=)
AU (1) AU2005230837A1 (https=)
BR (1) BRPI0509468A (https=)
CA (1) CA2561738A1 (https=)
DE (1) DE602005027677D1 (https=)
IL (1) IL178167A0 (https=)
MA (1) MA28562B1 (https=)
NO (1) NO20064982L (https=)
NZ (1) NZ550857A (https=)
RU (1) RU2375358C2 (https=)
WO (1) WO2005097762A2 (https=)
ZA (1) ZA200607851B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005230838A1 (en) * 2004-04-01 2005-10-20 Aventis Pharmaceuticals Inc. 1,3,4-oxadiazol-2-ones as PPAR delta
DE602005024384D1 (de) 2004-05-05 2010-12-09 High Point Pharmaceuticals Llc Neue verbindungen, ihre herstellung und verwendung
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
ES2372617T3 (es) 2005-06-30 2012-01-24 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de ppar-delta.
AU2006299092A1 (en) * 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl-(1,2,4)-oxadiazol-5-one derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals
JP2009509988A (ja) 2005-09-29 2009-03-12 サノフィ−アベンティス フェニル−及びピリジニル−１，２，４−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
CN103224477A (zh) 2005-12-22 2013-07-31 高点制药有限责任公司 作为PPAR-δ活化剂的苯氧基乙酸
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
US20080004281A1 (en) * 2006-06-28 2008-01-03 Kalypsys, Inc. Methods for the modulation of crp by the selective modulation of ppar delta
US20120020931A1 (en) * 2010-06-02 2012-01-26 Rutgers, The State University Of New Jersey Therapeutic encapsulated embryonic stem cells and mesenchymal stromal cells
EP3756661A1 (en) 2013-09-09 2020-12-30 vTv Therapeutics LLC Use of a ppar-delta agonist for treating muscle atrophy
WO2021092279A1 (en) * 2019-11-06 2021-05-14 Board Of Regents, The University Of Texas System Methods for the treatment of dysmyelinating/demyelinating diseases
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4895953A (en) * 1987-09-30 1990-01-23 American Home Products Corporation 2-Aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US5103014A (en) * 1987-09-30 1992-04-07 American Home Products Corporation Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives
US4826990A (en) * 1987-09-30 1989-05-02 American Home Products Corporation 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
ES2277842T3 (es) * 1999-06-18 2007-08-01 MERCK & CO., INC. Derivados de ariltiazolidindiona y de ariloxazolidindiona.
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
US6506781B1 (en) * 1999-09-08 2003-01-14 Smithkline Beecham Corporation Oxazole PPAR antagonist
JP4145230B2 (ja) * 2002-11-01 2008-09-03 武田薬品工業株式会社 神経障害の予防・治療剤
TW200505441A (en) * 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
AU2005230838A1 (en) * 2004-04-01 2005-10-20 Aventis Pharmaceuticals Inc. 1,3,4-oxadiazol-2-ones as PPAR delta

Also Published As

Publication number Publication date
WO2005097762A2 (en) 2005-10-20
RU2375358C2 (ru) 2009-12-10
CN1938305A (zh) 2007-03-28
JP2007531763A (ja) 2007-11-08
US20070060626A1 (en) 2007-03-15
MA28562B1 (fr) 2007-04-03
NZ550857A (en) 2009-12-24
IL178167A0 (en) 2006-12-31
RU2006138485A (ru) 2008-05-10
EP1735303A2 (en) 2006-12-27
ZA200607851B (en) 2008-06-25
US7576109B2 (en) 2009-08-18
DE602005027677D1 (de) 2011-06-09
AU2005230837A1 (en) 2005-10-20
JP4813460B2 (ja) 2011-11-09
BRPI0509468A (pt) 2007-09-11
KR20060135854A (ko) 2006-12-29
ATE507226T1 (de) 2011-05-15
CN100516065C (zh) 2009-07-22
NO20064982L (no) 2006-10-31
WO2005097762A3 (en) 2005-12-15
EP1735303B1 (en) 2011-04-27

Similar Documents

Publication Publication Date Title
US7872032B2 (en) 1, 3, 4-oxadiazol-2-ones as PPAR delta modulators and their use thereof
JP4658073B2 (ja) グアニジン化合物および５−ｈｔ５受容体への結合相手としてのそれの使用
RU2283841C2 (ru) Азолильные производные хинолина и хиназолина, содержащая их фармацевтическая композиция, их применение и способ лечения заболеваний
AU2013283318B2 (en) Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders
EP1735303B1 (en) 1,3,4-oxadiazol-2-ones as ppar delta modulators and their use thereof
US20040063775A1 (en) Five-membered heterocyclic alkanoic acid derivative
AU2009272033B2 (en) Nitrogenated heterocyclic compound
JP3602513B2 (ja) アゾリル基を有するキノリン誘導体およびキナゾリン誘導体
JP2002332266A (ja) ＰＰＡＲ−γモジュレータ
KR20010053282A (ko) 레티노이드-관련 수용체 기능 조절제
US20200223837A1 (en) Benzofuran amides and heteroaromatic analogues thereof for use in therapy
JP2009132620A (ja) フェニルチアゾール誘導体
WO2005077124A2 (en) Compounds and compositions as lxr modulators
CN102558167A (zh) Gk和ppar双重激动活性的噻唑烷二酮衍生物
MXPA06010935A (en) 1,3,4-oxadiazol-2-ones as ppar delta modulators
MXPA06011064A (es) 1,3,4-oxadiazol-2-onas como moduladores de ppardelta y su uso
KR20070021171A (ko) Ｐｐａｒ 델타 조절물질로서의 1,3,4-옥사디아졸-2-온
JP2004224800A (ja) アゾリル基を有するキノリン誘導体およびキナゾリン誘導体

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued